Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.65 |
| ▸ | SLC6A7 | Q99884 | 3/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14686594 | 0.87 | PRCP (0.60) | PRCPSLC6A7HSD11B1SMN1; SMN2MAPT | |
| SCHEMBL2599440 | 0.85 | PRCP (0.55) | PRCPMAPTCNR1KDM4EMEN1 | |
| SCHEMBL12186022 | 0.83 | PRCP (0.68) | PRCP | |
| SCHEMBL12185983 | 0.80 | PRCP (0.85) | PRCP | |
| SCHEMBL12185513 | 0.80 | PRCP (0.62) | PRCPSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL14737070 | 0.79 | PRCP (0.54) | PRCPSLC6A7HSD11B1SMN1; SMN2MAPT | |
| SCHEMBL12185580 | 0.79 | PRCP (1.00) | PRCPMEN1KMT2A | |
| SCHEMBL14736875 | 0.79 | PRCP (0.59) | PRCPSLC6A7KDM4EMEN1KMT2A | |
| SCHEMBL12185581 | 0.79 | PRCP (1.00) | PRCPKDM4EMEN1KMT2A | |
| SCHEMBL12185577 | 0.78 | PRCP (0.86) | PRCPSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2568812-B1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9365539-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | PRCP 1/4885SLC6A7 518/4885HSD11B1 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.